8-K: Zevra Therapeutics Announces Positive Phase 2 Trial Results for KP1077 in Idiopathic Hypersomnia

Zevra Therapeutics reported positive final results from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia, showing the drug was well-tolerated and produced clinically meaningful improvements in patient-reported outcomes.

Summary

• Zevra Therapeutics announced positive final results from its Phase 2 clinical trial of KP1077 (serdexmethylphenidate or SDX) for the treatment of idiopathic hypersomnia (IH).
• The trial was a placebo-controlled, double-blind study designed to assess safety and tolerability, and it was not powered to demonstrate statistical significance.
• KP1077 was well-tolerated at all dose levels, including the highest dose of 320 mg daily, with adverse events similar to other methylphenidate products.
• The most common adverse events included insomnia, headache, anxiety, decreased appetite, and nausea, mostly occurring during the titration period and were mild.
• Patients showed clinically meaningful improvements in excessive daytime sleepiness (EDS), sleep inertia, and brain fog.
• Mean total Epworth Sleepiness Scale (ESS) scores decreased by approximately 9 points after 5 weeks of open-label treatment.
• At the end of 7 weeks, mean total ESS scores decreased by 9.4 (QD) and 8.8 (BID), mean total IH Severity Scale (IHSS) scores decreased by 16.1 (QD) and 12.3 (BID), mean Sleep Inertia Visual Analog Scale (SIVAS) scores decreased by 25.9 (QD) and 17.2 (BID), and mean total Brain Fog Scale (BFS) symptom scores decreased by 23.8 (QD) and 22.3 (BID).
• The study also investigated the pharmacokinetics of morning and nighttime doses of KP1077, finding that nighttime dosing leads to higher exposure at awakening.
• The results support the initiation of a Phase 3 trial of KP1077.

Sentiment

Score: 8

Explanation: The document presents positive results from a Phase 2 trial, indicating a potential new treatment for a rare disease. The language is optimistic and the results are described as clinically meaningful, suggesting a positive outlook for the company.

Positives

• KP1077 demonstrated a good safety profile, with adverse events comparable to other methylphenidate products.
• The drug showed clinically significant improvements in multiple patient-reported outcomes, including daytime sleepiness, sleep inertia, and brain fog.
• The study identified that nighttime dosing of KP1077 may be more effective for patients experiencing sleep inertia.
• The results support the progression of KP1077 to a Phase 3 clinical trial.

Negatives

• The most common adverse events included insomnia, headache, anxiety, decreased appetite, and nausea, although these were mostly mild and occurred during the titration period.
• The study was not powered to demonstrate statistical significance, as it was primarily designed to assess safety and tolerability.

Risks

• The study was not powered to demonstrate statistical significance, so further trials are needed to confirm efficacy.
• Adverse events, although mild, were reported and need to be monitored in future trials.
• The success of a Phase 3 trial is not guaranteed, and regulatory approval is still required.

Future Outlook

The company plans to use the data from this Phase 2 trial to inform the design of a potential Phase 3 clinical trial for KP1077, with the goal of bringing a new treatment option to patients with idiopathic hypersomnia.

Management Comments

• Adrian Quartel, MD, FFPM, Chief Medical Officer of Zevra, stated that they are encouraged by the positive results of the Phase 2 clinical trial, which serve as further support of KP1077 as a strong candidate to treat patients struggling with idiopathic hypersomnia.
• Christopher Drake, PhD, FAASM, DBSM, Principal Investigator of the study, stated that the results of the Phase 2 clinical trial support the safety and tolerability of KP1077 and that the clinically meaningful impact for both the safety and efficacy were well demonstrated by patients showing significant improvements in IH symptom severity.

Industry Context

This announcement is significant in the rare disease therapeutics space, particularly for sleep disorders, as it highlights a potential new treatment option for idiopathic hypersomnia, a condition with limited existing therapies. The positive results could position Zevra as a key player in this niche market.

Comparison to Industry Standards

• The reported adverse events of KP1077 are similar to other methylphenidate products, which is consistent with industry standards for this class of drugs.
• The clinically meaningful improvements in ESS, IHSS, SIVAS, and BFS scores are comparable to or better than results seen in trials of other treatments for sleep disorders, though direct comparisons are difficult due to variations in study design and patient populations.
• The focus on patient-reported outcomes aligns with current trends in clinical research, emphasizing the importance of patient experience in evaluating treatment efficacy.
• The study's findings on nighttime dosing of SDX are novel and could differentiate KP1077 from other methylphenidate-based treatments.

Stakeholder Impact

• Shareholders may react positively to the news of successful Phase 2 trial results.
• Patients with idiopathic hypersomnia may benefit from a new treatment option.
• The medical community may be interested in the potential of KP1077.
• Employees of Zevra may be motivated by the progress of the company's pipeline.

Next Steps

• The company plans to use the Phase 2 data to inform the design of a potential Phase 3 clinical trial.
• Zevra will continue to present data at scientific meetings and engage with the medical community.

Key Dates

Keywords

Idiopathic Hypersomnia, KP1077, Serdexmethylphenidate, SDX, Phase 2 Clinical Trial, Sleep Disorder, Excessive Daytime Sleepiness, Sleep Inertia, Brain Fog, Methylphenidate